1′-Acetoxychavicol Acetate Increases Proteasome Activity by Activating cAMP-PKA Signaling

Keisuke Yaku; Isao Matsui-Yuasa; Akiko Kojima-Yuasa

doi:10.1055/s-0043-118806

Planta Medica, Table of Contents

Planta Med 2018; 84(03): 153-159
DOI: 10.1055/s-0043-118806

Biological and Pharmacological Activity

Original Papers

Georg Thieme Verlag KG Stuttgart · New York

1′-Acetoxychavicol Acetate Increases Proteasome Activity by Activating cAMP-PKA Signaling

Authors

Keisuke Yaku

Department of Food and Human Health Sciences, Graduate School of Human Life Science, Osaka City University, Osaka, Japan
Isao Matsui-Yuasa

Department of Food and Human Health Sciences, Graduate School of Human Life Science, Osaka City University, Osaka, Japan
Akiko Kojima-Yuasa

Department of Food and Human Health Sciences, Graduate School of Human Life Science, Osaka City University, Osaka, Japan

Abstract

Protein degradation systems are critical pathways for the maintenance of protein homeostasis. The age-dependent attenuation of the proteasome activity contributes to age-related neurodegenerative processes. The molecule 1′-acetoxychavicol acetate (ACA) is naturally obtained from the rhizomes and seeds of Zingiberaceae plants, such as Languas galangal and Alpinia galangal, and exhibits anti-carcinogenic effects. Recently, we have shown that ACA protected the age-related learning and memory impairments in senescence-accelerated mice and maintained cognitive performance. Therefore, we here examined the effects of ACA on the protein degradation systems and cell protection against neurotoxicity in differentiated PC12 cells. ACA increased proteasome activity in PC12 cells. Increased proteasome activity occurred during the initial stages of ACA treatment and lasted at least 9 h. The activity returned to control levels within 24 h. The increase in proteasome activity by ACA was suppressed by H-89, which is a cAMP-dependent protein kinase A inhibitor. ACA increased the adenylate cyclase activity and therefore the intracellular cAMP levels. Furthermore, ACA recovered the initial cell viability, which was reduced after the addition of the amyloid β-protein fragment to neuronally differentiated PC12 cells. The effects of ACA on amyloid toxicity were reduced after treatment with MG132, a proteasome inhibitor. These results demonstrated a neuroprotective effect of ACA via activation of cAMP/cAMP-dependent protein kinase A signaling in neuronally differentiated PC12 cells.

Key words

1′-acetoxychavicol acetate - proteasome - AMP-dependent protein kinase A - adenylate cyclase - cAMP - amyloid β - PC12 cells

Full Text

References

References
1 Hiller MM, Finger A, Schweiger M, Wolf DH. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 1996; 273: 1725-1728
2 DeMartino GN, McCullough ML, Reckelhoff JF, Croall DE, Ciechanover A, McGuire MJ. ATP-stimulated degradation of endogenous proteins in cell-free extracts of BHK 21/C13 fibroblasts. A key role for the proteinase, macropain, in the ubiquitin-dependent degradation of short-lived proteins. Biochim Biophys Acta 1991; 1073: 299-308
3 Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479
4 Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-protease system. Nat Rev Drug Discov 2006; 5: 596-613
5 Carrard G, Bulteau AL, Petropoulos I, Friguet B. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 2002; 34: 1461-1474
6 Forloni G, Terreni L, Bertani I, Fogliarino S, Invernizzi R, Assini A, Ribizzi G, Negro A, Calabrese E, Volonté MA, Mariani C, Franceschi M, Tabaton M, Bertoli A. Protein misfolding in Alzheimerʼs and Parkinsonʼs disease: genetics and molecular mechanisms. Neurobiol Aging 2002; 23: 957-976
7 Wisniewski HM, Silverman W. Diagnostic criteria for the neuropathological assessment of Alzheimerʼs disease: current status and major issues. Neurobiol Aging 1997; 18: S43-S50
8 Tomita T. Molecular mechanism of intramembrane proteolysis by c-secretase. J Biochem 2014; 156: 195-201
9 Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/a-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001; 78: 899-908
10 Metcalfe MJ, Huang Q, Figueredo-Pereira ME. Coordination between protease impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP. Cell Death Dis 2012; 3: e326
11 Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 2016; 22: 46-53
12 Kojima-Yuasa A, Yamamoto T, Yaku K, Hirota S, Tskenaka S, Kawabe K, Matsui-Yuasa I. 1′-Acetoxychavicol acetate ameliorates age-related spatial memory deterioration by increasing serum ketone body production as a complementary energy source for neuronal cells. Chem Biol Inter 2016; 257: 101-109
13 Ohnishi R, Matsui-Yuasa I, Deguchi Y, Yaku K, Tabuchi M, Munakata H, Akahoshi Y, Kojima-Yuasa A. 1′-Acetoxychavicol acetate inhibits adipogenesis in 3T3-L1 adipocytes and in high fat-fed rats. Am J Chin Med 2012; 40: 1189-1202
14 Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, Kudlow JE. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 2007; 282: 22460-22471
15 Djakovic SN, Schwarz LA, Barylko B, DeMartino GN, Patrick GN. Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II. J Biol Chem 2009; 284: 26655-26665
16 Rinaldi L, Sepa M, Donne RD, Feliciello A. A dynamic interface between ubiquitylation and cAMP signaling. Front Pharmacol 2015; 6: 177
17 Taylor SS. cAMP-dependent protein kinases. J Biol Chem 1989; 164: 8443-8446
18 Huang Q, Figueiredo-Pereira ME. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 2010; 15: 1292-1311
19 Iwafune Y, Kawasaki H, Hirano H. Electrophoretic analysis of phosphorylation of the yeast 20S proteasome. Electrophoresis 2002; 23: 329-338
20 Kikuchi J, Iwafune Y, Akiyama T, Okayama A, Nakamura H, Arakawa N, Kimura Y, Hirano H. Co- and post-translational modifications of the 26S proteasome in yeast. Proteomics 2010; 10: 2769-2779
21 Myeku N, Wang H, Figueiredo-Pereira ME. cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons. Neurosci Lett 2012; 527: 126-131
22 Lin JT, Chang WC, Chen HM, Lai HL, Chen CY, Tao MH, Chern Y. Regulation of feedback between protein kinase A and the proteasome system worsens Huntingtonʼs disease. Mol Cell Biol 2013; 33: 1073-1084
23 Hansen TV, Rehfeld JF, Nielsen FC. KCl potentiates folskolin-induced PC12 cell neurite outgrowth via protein kinase A and extracellular signal-regulated kinase signaling pathways. Neurosci Lett 2003; 347: 57-61
24 Sanchez S, Jimenez C, Carrera AC, Diaz-Nido J. Avila J, Wandosell FA. cAMP-activated pathway, including PKA and PI3K, regulates neuronal differentiation. Neurochem Int 2004; 44: 231-242
25 Lambeng N, Michel PP, Agid Y, Ruberg M. The relationship between differentiation and survival in PC12 cells treated with cyclic adenosine monophosphate in the presence of epidermal growth factor or nerve growth factor. Neurosci Lett 2001; 297: 133-136
26 Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421
27 Rubinsztein DC. The role of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786
28 Utano T, Takahashi S, Ishizu A, Miyatake Y, Gohda A, Suzuki S, Ono A, Ohara J, Baba T, Murata S, Tanaka K, Kasahara M. Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities. Am J Pathol 2012; 180: 963-972
29 Torres C, Lewis L, Cristofalo VJ. Proteasome inhibitors shorten replicative life span and induce a senescent-like phenotype of human fibroblasts. J Cell Physiol 2006; 207: 845-853
30 Kruegel U, Robison B, Dange T, Kahlert G, Delaney JR, Kotireddy S, Tsuchiya M, Tsuchiyama S, Murakami CJ, Schleit J, Sutphin G, Carr D, Tar K, Dittmar G, Kaeberlein M, Kennedy BK, Schmidt M. Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae . PLoS Genet 2011; 7: e1002253
31 Foster NL, Chase P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimerʼs disease: focal cortical changes shown by positoron emission tomography. Neurology 1983; 33: 961-965
32 Nugest S, Castellano CA, Goffaux P, Whittingstall K, Lepage M, Paquest N, Bocti C, Fulop T, Cunnane SC. Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. Am J Physiol Endcrinol Metab 2014; 306: E1315-E2321
33 Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M. TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Cancer Sci 2015; 106: 438-446
34 Moffatt J, Hashimoto M, Kojima A, Kennedy DO, Murakami A, Koshimizu K, Ohigashi H, Matsi-Yuasa I. Apoptosis induced 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation. Carcinogenesis 2000; 21: 2151-2157
35 Xu S, Kojima-Yuasa A, Azuma H, Kennedy DO, Konishi Y, Matsui-Yuasa I. Comparison of glutathione reductase activity and the intracellular glutathione reducing effects of 13 derivatives of 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem Biol Interact 2010; 185: 235-240
36 Azuma H, Aizawa Y, Higashitani N, Tsumori T, Kojima-Yuasa A, Matsui-Yuasa I, Nagasaki T. Biological activity of water-soluble inclusion complexes of 1′-acetoxychavicol acetate with cyclodextrins. Bioorg Med Chem 2011; 19: 3855-3863
37 Yaku K, Matsui-Yuasa I, Konishi Y, Kojima-Yuasa A. AMPK synergizes with the combined treatment of 1′-acetoxychaviol acetate and sodium butyrate to upregulate phase II detoxifying enzyme activites. Mol Nutr Food Res 2013; 57: 1198-1208
38 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
39 Reysz LJ, Carroll AG, Jarrett HW. An automated-assay for adenylate-cyclase using reversed-phase high-performance liquid-chromatography. Anal Biochem 1987; 166: 107-112